Please ensure Javascript is enabled for purposes of website accessibility

Valeant Pharmaceuticals Intl. Inc. Jumped 27% in April, But It's Not Out of the Woods

By Sean Williams - May 3, 2016 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A few things finally go right in April for Valeant, but that doesn't mean the tide has turned.

Image source: Centers for Disease Control and Prevention.

What: Shares of Valeant Pharmaceuticals (BHC -1.76%), the embattled drug developer that primarily grows through buyouts and price hikes, jumped by 27% in April based on data from S&P Global Market Intelligence. The reason for the jump relates to two key events during the month.

So what: Most importantly, Wall Street and investors found out early in April that Valeant had worked out a debt default waiver with its secured credit lenders, which hold more than $11 billion of Valeant's nearly $31 billion in outstanding debt. The deal saw Valeant agree to pay a fee of $50,000 for every $10 million it's borrowed, as well as increase its lending rate by a full percentage point, in exchange for getting until April 29 to file its annual report. Valeant did indeed make good on this promise by filing its 10-K on April 29, appeasing those secured debtholders.

J. Michael Pearson. Image source: Valeant Pharmaceuticals.

The other major catalyst in April was the announcement that Perrigo (PRGO -0.98%) CEO Joseph Papa would be taking over as Valeant CEO. In March, just weeks after returning from a two-month medical absence, J. Michael Pearson announced that he would step down from leading Valeant. Papa has done a very good job growing Perrigo, a branded and generic therapeutics company, since he became CEO a decade earlier. Sales for Perrigo more than tripled to $4.6 billion since 2006, while net income, though bumpy at times, also rose nicely. Papa's presence could help calm nervous Valeant investors.

Now what: Unfortunately, Valeant and its shareholders aren't out of the woods yet. The company's 10-K filing disclosed three total probes, and it's still dealing with potential pricing scrutiny from U.S. lawmakers after J. Michael Pearson took to the Hill to be deposed on Valeant's pricing practices. If prescription drug reforms are enacted, or if fines are headed Valeant's way, it could be another major blow to the company.

Additionally, Valeant could be looking to reduce its leverage by unloading some of the assets it's acquired. The problem is that if Valeant doesn't sell enough assets, it'll still be buried under a lot of debt. But, if it gets rid of highly valued assets, such as Bausch & Lomb, it might give up too much in terms of future growth, jeopardizing its ability to service a much smaller debt load.

But the biggest issue of all is that there's essentially no long-term business model clarity. There's no guarantee that Valeant will be able to grow by acquisition since it has basically no additional access to financing at the moment, and its existing R&D programs may not deliver enough real-world growth to satisfy a valuation that's already been reduced by more than 85%.

My suggestion remains the same as it's been for months: steer clear of Valeant and watch patiently from the sidelines until we have more clarity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$8.36 (-1.76%) $0.15
Perrigo Company plc Stock Quote
Perrigo Company plc
$40.57 (-0.98%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.